To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer

INDICATION: Pancreatic cancer

Patient sample and mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, high levels of CXCR2 in neutrophils at the tumor borders

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE